中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Zaiming to present the latest clinical progresses of three products in its portfolio at WCLC 2023

Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd., announced today that ...

2023-09-04
The First Subject Dosed with SIM0278, an Innovative IL-2 mu-Fc Independently Developed by Simcere Pharmaceutical

On Aug. 26, 2023, SIM0278, an innovative interleukin 2 mutant fusion protein (IL-2 mu-Fc) independently developed by Simcere Pharmaceutical (2096. HK)...

2023-08-26
Positive Results from Phase II Clinical Study of JAK1 Inhibitor for AS Treatment Jointly Introduced by Simcere Pharmaceutical and Lynk Pharmaceuticals

On Aug. 23, 2023, Simcere Pharmaceutical Co., Ltd. (“Simcere”) and Lynk Pharmaceuticals (Hangzhou) Co., Ltd. ( “Lynk Pharmaceuticals”) announced posit...

2023-08-23
Simcere Zaiming Partners with MabPharm on anti-EGFR Monoclonal Antibody CMAB009 in China

On August 20, 2023, Simcere Zaiming Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Simcere pharmaceutical Group Ltd., ("Simcere Zaiming”)...

2023-08-22
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.